V.N. Zhurman1,2

1Primorsky Regional Oncological Dispensary, Vladivostok

2Pacific State Medical University, Vladivostok

Zhurman Varvara N. — Cand. of Sci. (Med.), oncologist of the Primorsky Regional Oncological Dispensary

63А Russkaya Str., Vladivostok, 690105, Russian Federation, tel. +7-904-622-25-77, e-mail:, ORCID ID: 0000-0002-6927-3336

Abstract. Malignant neoplasms of the ovaries of epithelial nature account for 90%, of which serous carcinomas account for up to 85%. Due to pronounced heterogeneity (at the molecular and genetic level) and chemoresistance, difficulties arise in finding active targets for tumor elimination. An immunohistochemical study of tumor material was carried out in 74 patients with serous ovarian cancer treated in the period from 2016 to 2021. To determine the antigens in the samples, monoclonal antibodies were used: CD3, CD4, CD8, CD11b, CD14 and CD16. The average age of the patients was 57±11 years. The comparative group included 70 patients with benign ovarian tumors. The obtained results of the immunohistochemical study showed that in the composition of the immune cells of the microenvironment, the largest number of cells, at all stages (I–IV) of the oncological process, are represented by macrophages (CD11b+, CD14+), CD3+ lymphocytes are in second place in terms of the number of cells, followed by CD8+ and CD4+ and the smallest number of CD16+ cells.

As a result of the immunohistochemical study, a multidirectional trend was found between the population composition of tumor-associated immune cells of the microenvironment and the stage of serous ovarian cancer. With an increase in the stage of the disease, the number of macrophages (CD11b+, CD14+) and lymphocytes (CD3+, CD16+) decreased regardless of the degree of differentiation of the tumor. With an increase in the tumor stage, the number of CD4+ and CD8+ populations decreased, but in this case, the degree of differentiation played a significant role, the higher the stage of the tumor and the lower the degree of differentiation, the fewer cells are detected.

Key words: serous ovarian cancer low-grade, high-grade, monoclonal antibodies: CD3, CD4, CD8, CD11b, CD14 and CD16.